Dorothea Papadopoulou

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial

Charalampos Loutradis, Pantelis Sarafidis, Robert Ekart et al. · Kidney International · 2019 · 99 citations · Full text

Medicine, Nephrology, Hemodialysis +12

Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease

Maria Eleni Alexandrou, Αikaterini Papagianni, Charalampos Loutradis et al. · Journal of Hypertension · 2019 · 97 citations

Medicine, Nephrology, Pharmacotherapy +16

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Rajiv Agarwal, Wanzhu Tu, Alfredo E. Farjat et al. · Annals of Internal Medicine · 2023 · 88 citations

Medicine, Pharmacology, Pharmacotherapy +17

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

Hiddo J.L. Heerspink, Rajiv Agarwal, George L. Bakris et al. · Nephrology Dialysis Transplantation · 2024 · 77 citations · Full text

Medicine, Nephrology, Pharmacotherapy +16